AI-Powered Platform Enables Rapid Point-of-Care Cancer Testing

One of the major hurdles in oncology is performing advanced genomic testing quickly enough to provide oncologists with actionable results that can lead to the best possible patient outcomes. A new intelligent cancer solution aims to address this challenge by enabling labs and oncologists globally to accelerate targeted treatments, ultimately reducing costs while enhancing patient-focused care.

Avitia (Montreal, Canada) has introduced an artificial intelligence (AI)-powered rapid cancer testing platform that grants laboratories and clinicians access to advanced molecular testing directly on-site, regardless of their location. This innovation enables healthcare teams to quickly gather cancer insights and initiate treatment at a faster pace, all while offering a more cost-effective alternative to existing send-out testing methods. Research has shown that long travel distances remain a significant barrier to accessing high-quality cancer care, which directly impacts patient outcomes. Avitia’s modular technology enables cancer centers to perform NGS tests on-site, cutting down turnaround times and reducing expenses compared to centralized labs that rely on send-out services.

Image: An AI-powered platform for rapid cancer testing empowers labs and oncologists worldwide to accelerate targeted treatments (Photo courtesy of Avitia)

With AI-driven bioinformatics designed to meet regional and patient-specific needs, Avitia helps oncologists overcome logistical challenges and test patients more efficiently. These data-driven insights ensure that every patient receives care that is both precise and personalized. Utilizing minimally invasive liquid biopsy technology, Avitia’s platform has shown promise in improving patient monitoring and treatment responses, particularly for aggressive endometrial and ovarian cancers. A recent retrospective study highlighted that Avitia’s liquid biopsy technology enabled researchers to detect disease recurrence months before conventional clinical, radiologic, and biomarker progression methods. Currently, Avitia’s technology is being used by partners in Canada, the United States, and Southeast Asia, with over 40,000 life-saving cancer mutation tests already conducted using this platform.

“Avitia believes that all patients deserve access to advanced, cost-effective testing, regardless of geographic or economic constraints,” said Avitia CEO James Lumsdaine.

Related Links:
Avitia